JPWO2020219681A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020219681A5 JPWO2020219681A5 JP2021562989A JP2021562989A JPWO2020219681A5 JP WO2020219681 A5 JPWO2020219681 A5 JP WO2020219681A5 JP 2021562989 A JP2021562989 A JP 2021562989A JP 2021562989 A JP2021562989 A JP 2021562989A JP WO2020219681 A5 JPWO2020219681 A5 JP WO2020219681A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- antibody
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837518P | 2019-04-23 | 2019-04-23 | |
| US62/837,518 | 2019-04-23 | ||
| US201962859699P | 2019-06-10 | 2019-06-10 | |
| US62/859,699 | 2019-06-10 | ||
| EP20305145.3 | 2020-02-17 | ||
| EP20305145 | 2020-02-17 | ||
| EP20305146 | 2020-02-17 | ||
| EP20305146.1 | 2020-02-17 | ||
| PCT/US2020/029531 WO2020219681A1 (fr) | 2019-04-23 | 2020-04-23 | Formulations et anticorps anti-cd38 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022529502A JP2022529502A (ja) | 2022-06-22 |
| JPWO2020219681A5 true JPWO2020219681A5 (fr) | 2023-05-01 |
Family
ID=70739160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562989A Pending JP2022529502A (ja) | 2019-04-23 | 2020-04-23 | 抗ｃｄ３８抗体および製剤 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP3958898A1 (fr) |
| JP (1) | JP2022529502A (fr) |
| KR (1) | KR20220003562A (fr) |
| CN (1) | CN114269375A (fr) |
| AU (1) | AU2020261039A1 (fr) |
| BR (1) | BR112021021060A2 (fr) |
| CA (1) | CA3137365A1 (fr) |
| CO (1) | CO2021015462A2 (fr) |
| IL (1) | IL287477A (fr) |
| MA (1) | MA55761A (fr) |
| MX (1) | MX2021012967A (fr) |
| SG (1) | SG11202111602YA (fr) |
| TW (1) | TW202104269A (fr) |
| WO (1) | WO2020219681A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024023843A1 (fr) * | 2022-07-26 | 2024-02-01 | Dr. Reddy’S Laboratories Limited | Formulation pharmaceutique d'un anticorps thérapeutique et ses préparations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2112162T3 (da) | 2004-07-10 | 2015-02-23 | Fox Chase Cancer Ct | Genetisk modificerede humane naturlige dræbercellelinjer |
| EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
| CN109022465B (zh) * | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| MA43187B1 (fr) * | 2015-11-03 | 2021-02-26 | Janssen Biotech Inc | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations |
| CN108752475B (zh) * | 2018-06-14 | 2021-07-30 | 北京智仁美博生物科技有限公司 | 抗人cd38抗体及其用途 |
-
2020
- 2020-04-23 EP EP20726267.6A patent/EP3958898A1/fr active Pending
- 2020-04-23 SG SG11202111602YA patent/SG11202111602YA/en unknown
- 2020-04-23 MA MA055761A patent/MA55761A/fr unknown
- 2020-04-23 JP JP2021562989A patent/JP2022529502A/ja active Pending
- 2020-04-23 BR BR112021021060A patent/BR112021021060A2/pt unknown
- 2020-04-23 AU AU2020261039A patent/AU2020261039A1/en active Pending
- 2020-04-23 WO PCT/US2020/029531 patent/WO2020219681A1/fr unknown
- 2020-04-23 CN CN202080030148.3A patent/CN114269375A/zh active Pending
- 2020-04-23 CA CA3137365A patent/CA3137365A1/fr active Pending
- 2020-04-23 KR KR1020217037641A patent/KR20220003562A/ko unknown
- 2020-04-23 MX MX2021012967A patent/MX2021012967A/es unknown
- 2020-04-23 TW TW109113639A patent/TW202104269A/zh unknown
-
2021
- 2021-10-21 IL IL287477A patent/IL287477A/en unknown
- 2021-11-17 CO CONC2021/0015462A patent/CO2021015462A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220089668A1 (en) | Targeted mutant interferon-beta and uses thereof | |
| US10988538B2 (en) | Bispecific signaling agents and uses thereof | |
| KR102412023B1 (ko) | 레날리도마이드 또는 포말리도마이드 및 ｃｄ38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도 | |
| EP2964674B1 (fr) | Anticorps bispécifiques anti-tnf-anti-il-17 | |
| RU2748024C2 (ru) | Составы на основе антитела к CD19 | |
| US10858425B2 (en) | Pan-ELR+ CXC chemokine antibodies | |
| CN104902914B (zh) | 高纯度和优异产量的正确折叠的依那西普 | |
| US20220177550A1 (en) | Chimeric proteins and chimeric protein complexes directed to fms-like tyrosine kinase 3 (flt3) | |
| KR102171669B1 (ko) | 조합물 및 이의 용도 | |
| US20120045445A1 (en) | Method of treating viral diseases | |
| EP3580230A1 (fr) | Protéines chimères bispécifiques ciblées par des cellules immunitaires, et utilisations associées | |
| CA2901468C (fr) | Anticorps pan-elr+ cxc chimiokine | |
| JP2010518079A5 (fr) | ||
| KR102576368B1 (ko) | 항-il-25 항체 및 그것의 사용 | |
| CN113797333A (zh) | 一种新型冠状病毒抗体的药物组合物及其用途 | |
| US20190135934A1 (en) | Anti-cd20 targeted antibody, and uses and technical field | |
| KR20200033302A (ko) | Nkg2d, cd16 및 flt3에 결합하는 단백질 | |
| CN114762678B (zh) | 抗tigit抗体药物组合物及其用途 | |
| WO2022135395A1 (fr) | Préparation d'anticorps stable, son procédé de préparation et ses applications | |
| WO2016162867A1 (fr) | Thérapie combinée composée d'un facteur d'activation des macrophages et d'inhibiteurs de la voie de signalisation pd-1 | |
| JP2024512714A (ja) | 融合タンパク質、医薬組成物、及び治療適用 | |
| KR20210078473A (ko) | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 | |
| JPWO2020219681A5 (fr) | ||
| RU2006101166A (ru) | Рекомбинантные антитела и композиции и способы их получения и использования | |
| RU2021133923A (ru) | Антитела к cd38 и составы |